Recent advances in novel formulation approaches for tacrolimus delivery in treatment of various ocular diseases

Kailasam, Velmurugan; Cheruvu, Sai Shreya; Malani, Manisha; Kameswari, Srujana Mosalikanti Sai; Kesharwani, Prashant; Nirmal, Jayabalan

doi:10.1016/j.jddst.2022.103945

Cited by 7 publications

(5 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23] Although there are commercially available DED eye drops containing Tacrolimus, such formulations often result in moderate ocular irritation following administration. [47] Moreover, the bioavailability of Tacrolimus is greatly limited as it is both hydrophobic and has a high molecular weight (804 g/mol). [48] This present study aims to not only construct an ophthalmic formulation that can extend the residence time of Tacrolimus in the cornea but also improve biocompatibility.…”

Section: Dry Eye Diseasementioning

confidence: 99%

“…explored the use of Poloxamer 188 and Poloxamer 407 as a carrier for Tacrolimus [23] . Although there are commercially available DED eye drops containing Tacrolimus, such formulations often result in moderate ocular irritation following administration [47] . Moreover, the bioavailability of Tacrolimus is greatly limited as it is both hydrophobic and has a high molecular weight (804 g/mol) [48] .…”

Section: Ophthalmic Applications Of Hydrogelsmentioning

confidence: 99%

See 1 more Smart Citation

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Kulbay,

Wu,

Truong

et al. 2024

Smart Molecules

View full text Add to dashboard Cite

This comprehensive review delves into a unique intersection of hydrogels as smart molecules and their transformative applications in ophthalmology. Beginning with the foundational definition, properties, and classification of hydrogels, the review explores their synthesis and responsive capabilities. Specific applications examined encompass topical drug delivery, contact lenses, intravitreal drug delivery, ocular adhesives, vitreous substitutes, and cell‐based therapy. A methodical analysis, including an overview of relevant ocular structures and a comparative evaluation of hydrogel‐based solutions against traditional treatments, is conducted. Additionally, potential constraints, translation challenges, knowledge gaps, and research areas are identified. Our methodical approach, guided by an extensive literature review from 2017 to 2023, illuminates the unprecedented opportunities offered by hydrogels, along with pinpointing areas for further inquiry to facilitate their transition into clinical practice.

show abstract

Section: Dry Eye Diseasementioning

confidence: 99%

Section: Ophthalmic Applications Of Hydrogelsmentioning

confidence: 99%

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Kulbay,

Wu,

Truong

et al. 2024

Smart Molecules

View full text Add to dashboard Cite

show abstract

“…Liposomes are extensively regarded and investigated as lipid-based drug delivery vehicles, not only due to the fundamental raw material for their manufacture, phospholipids, is an inherent element in human cells, making them friendly and non-immunogenic, but also since they can be manufactured as nanoscale particles, making them simpler to cross intrinsic limitations like blood vessel barriers and cellular membranes. In addition to antibacterial medication delivery, they are now employed in a variety of purposes, including as the treatment of cancer [81][82][83], eye illnesses [84,85], and neurodegenerative diseases [86,87].…”

Section: Lipid-based Nano-formulations As Antibacterial Theranosticsmentioning

confidence: 99%

Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections

Jiang¹,

Ding²,

Liu³

2023

Theranostics

View full text Add to dashboard Cite

Pathogenic bacterial infections represent an ever-growing crisis, now significantly threatening life expectancy across the worldwide population and thus novel approaches to tackle this issue are urgently needed. The application of nanotechnology in recent years has opened up new horizons in the selective or specific delivery of drugs or imaging agents to infectious sites. In particular, the development of nanoparticles for both delivery of active substances and imaging of infection sites is now gathering much interest. Although still in its infancy, the field of antibacterial nanomedicines provides exciting new possibilities to combat multi-resistant bacterial infections and shows great promise for personalized medicine in antibacterial stewardship. This review examines nanoparticle-based formulations used for therapeutic delivery, pathogen tracking in diagnosis, and combined “theranostic” approaches to more effectively treating bacterial infections.

show abstract

“…TAC (also refered to as Fujimycin, tsukubaenolide, or FK506) is a member of the L-pipecolic acid-derived macrolides class and has at least one deoxy sugar connected to a large macrocyclic 14-16-membered ring as part of its 23-membered lactone ring [26]. The molecular formula of TAC is C 44 H 69 NO 12 with a molecular weight of 803.5 Daltons and is generally found in a white to slightly off-white crystalline form.…”

Section: Tacrolimusmentioning

confidence: 99%

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis

Kale,

Shelke,

Lei

et al. 2023

Cells

View full text Add to dashboard Cite

Calcineurin inhibitors (CNI) can suppress allo- and autoimmunity by suppressing T cell function but also have anti-proteinuric effects by stabilizing the cellular components of the kidney’s filtration barrier. Therefore, CNI are used in autoimmune kidney diseases with proteinuria. However, the traditional CNI, cyclosporine A and tacrolimus, have a narrow therapeutic range, need monitoring of drug levels, and their use is associated with nephrotoxicity and metabolic alterations. Voclosporin (VOC), a novel CNI, no longer requires drug level monitoring and seems to lack these adverse effects, although hypertension and drug–drug interactions still occur. VOC demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase 2 AURA-LV and the phase 3 AURORA-1 trials and was approved for the treatment of active lupus nephritis. However, how to implement VOC into the current and changing treatment landscape of lupus nephritis is still debated. Here, we review the unique chemistry, pharmacology, and toxicity profile of VOC, summarize the efficacy and safety data from the AURA-LV and AURORA-1 trials, and discuss the following four possible options to implement VOC into the management of lupus nephritis, namely regarding B cell-targeting therapy with belimumab (BEL). These include: 1. patient stratification to either VOC or BEL, 2. VOC/BEL combination therapy, 3. VOC-BEL sequential therapy, or 4. alternative options for the rapid antiproteinuric effect of VOC.

show abstract

Recent advances in novel formulation approaches for tacrolimus delivery in treatment of various ocular diseases

Cited by 7 publications

References 125 publications

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis

Contact Info

Product

Resources

About